In a move to expand its ingredient portfolio and industry influence, Greenvit, a supplier specializing in aronia and berry extracts, has acquired a majority stake in Synkol, a Polish manufacturer specializing in collagen.

Synkol markets a type II chicken sternal cartilage collagen marketed under the Hyacoll brand. The company has been producing this line for dietary supplements and health products targeting joint, bone, and mobility support for more than ten years.

“With the acquisition of a majority stake of Synkol, we are strengthening our position in the nutraceutical ingredients market and broadening our technology base,” said Rafal Pietruszynski, CEO of Greenvit. “This strategic addition expands our capabilities by providing the global nutraceutical market with collagen-based ingredients.”

“This partnership elevates Synkol from a specialist manufacturer to a scalable player with global ambitions,” said Magdalena Chrzanowska, CEO of Synkol. Together with Greenvit, we can bring advanced collagen-based solutions to new markets and set a higher standard in nutraceutical innovation.”

“Greenvit brings Synkol not only capital, but a strategic partnership with deep expertise in building scalable operations,” said Joanna Iwankiewicz, Synkol board member. “Their expertise in quality management, regulatory processes, and international customer service strengthens the foundation on which we can grow responsibly and sustainably.”

While all collagen sources are performing well, there is robust interest in EU-origin chicken sternal cartilage-derived type II collagen, said Pietruszynski. “The market data supports our forward-thinking move into specialized type II collagen ingredients through the acquisition of Synkol and reinforces the message that Greenvit is evolving into a broader, science-driven supplier of high-value health ingredients.”